D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside

Author:

Barabássy Ágota1,Dombi Zsófia Borbála1,Németh György1

Affiliation:

1. Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary

Abstract

Until the late 1800s, drug development was a chance finding based on observations and repeated trials and errors. Today, drug development must go through many iterations and tests to ensure it is safe, potent, and effective. This process is a long and costly endeavor, with many pitfalls and hurdles. The aim of the present review article is to explore what is needed for a molecule to move from the researcher bench to the patients’ bedside, presented from an industry perspective through the development program of cariprazine. Cariprazine is a relatively novel antipsychotic medication, approved for the treatment of schizophrenia, bipolar mania, bipolar depression, and major depression as an add-on. It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients’ bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.

Publisher

MDPI AG

Reference68 articles.

1. Poduri, R. (2021). Drug Discovery and Development: From Targets and Molecules to Medicines, Springer.

2. Ng, R. (2009). Drugs: From Discovery to Approval, John Wiley & Sons, Inc.

3. Mann, S.K., and Marwaha, R. (2024, May 16). Chlorpromazine, Available online: https://www.ncbi.nlm.nih.gov/books/NBK553079/.

4. Bloom, F.E. (2024, May 16). Antianxiety Drug. Available online: https://www.britannica.com/science/antianxiety-drug.

5. Antidepressants: From MAOIs to SSRIs and More;Ramachandraih;Indian J. Psychiatry,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3